Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress and challenges in RET-targeted cancer therapy.

Frontiers of medicine - 1 Apr 2023

Hu Xueqing, Khatri Ujjwol, Shen Tao, Wu Jie

Abstract excerpt

The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 37131086
DOI: 10.1007/s11684-023-0985-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress and challenges in RET-targeted cancer therapy.PMID 37131086Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Semantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.